Welcome to our dedicated page for Ludwig Enter news (Ticker: LUDG), a resource for investors and traders seeking the latest updates and insights on Ludwig Enter stock.
Ludwig Enterprises, Inc. reports biotechnology developments centered on mRNA diagnostics, machine-learning analysis and non-invasive screening tests. Company news focuses on Revealia Breast, a cheek-swab breast cancer screening program that analyzes buccal cell mRNA biomarkers associated with inflammatory pathways, along with abstract publications tied to oncology research forums and journals.
Recurring updates also cover PCR validation work, provisional patent activity for cancer-screening algorithms, acquired intellectual property related to the mRNA Neuro Panel and Serotonin Assay, and governance changes as the company advances from research and diagnostic development toward healthcare solutions.
Ludwig Enterprises Inc. (OTC PINK:LUDG) announced the successful completion of its first round of new project funding, receiving $200,000 in private equity. The company has divested from its financial services unit to focus on technology and health-related projects. On May 18, 2022, Anne Blackstone was appointed CEO and sole director of mRNAforLife, Inc., a subsidiary aimed at health field acquisitions. Following Jean Cherubin's retirement on June 1, 2022, Blackstone also became CEO and Director of Ludwig Enterprises, indicating a strategic shift back to core business interests.
Ludwig Enterprises (OTC PINK:LUDG) announced a resolution to call $80,471.67 of convertible notes, leading to the issuance of 8,047,167 new common shares at $0.01 per share. The company is in the process of unwinding its relationship with Direct Mortgage Investors, resulting in an asset loss exceeding $600,000. Ludwig aims to focus on its core operations in technology and health-related fields. Additionally, it is monitoring third-party litigation related to ownership of 28 million shares.
Ludwig Enterprises Inc. has decided to unwind its subsidiary Direct Mortgage Investors, Inc., effective immediately. This move aims to refocus on technology and health-related sectors after Direct operated as a wholly owned subsidiary since 2019. Although Ludwig anticipates a short-term asset loss exceeding $600,000, the Board believes this strategic decision will enhance long-term shareholder value. Additionally, a third-party litigation regarding approximately 28 million Ludwig shares is being monitored, although neither party is involved in the case.